Data from Phase 1 and 2 clinical trials showed that a single injection of J&J vaccine produced sustained antibodies.
According to Arabnet, company scientists randomly selected healthy adults between the ages of 18 and 55 and those 65 years or older to receive a high or low dose From its vaccine - labeled Ad26.COV2.S and another placebo.
Some participants in the age group from 18 to 55 years were also selected to receive a second dose of the vaccine.
Most of the volunteers produced detectable neutral antibodies, which researchers believe play an important role in the cells' defense against the virus, after 28 days, according to the trial data. By day 57, all volunteers had detectable antibodies, regardless of vaccine dose or age group, and remained stable for at least 71 days in the 18-55 age group.
The most common side effects were fever, fatigue, headache, muscle aches and pain at the injection site, according to trial data. Side effects were less common in the older age group, who received only one dose of the vaccine, as well as in those who received a lower dose of the vaccine, according to the data.
The trial tested 805 volunteers, and the company is expected to announce the results of the third phase of the trial, involving 45,000 people, later this month.
The company is using the same technologies it used to develop the Ebola vaccine in its vaccine against Covid-19.
and, unlike vaccines from Pfizer and Moderna, which require two doses with an interval of three to four weeks, Johnson & Johnson requires only one dose, which will simplify logistics For health care providers.
and initial indications indicate that the vaccine can be stored at a temperature between 2 and 8 degrees Celsius for a period of 3 months.
